Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O14791
UPID:
APOL1_HUMAN
Alternative names:
Apolipoprotein L; Apolipoprotein L-I
Alternative UPACC:
O14791; A5PLQ4; B4DU12; E9PF24; O60804; Q5R3P7; Q5R3P8; Q96AB8; Q96PM4; Q9BQ03
Background:
Apolipoprotein L1 (ApoL1), with alternative names Apolipoprotein L and Apolipoprotein L-I, plays a crucial role in lipid transport and metabolism. It is instrumental in reverse cholesterol transport, a vital process for maintaining cellular cholesterol homeostasis.
Therapeutic significance:
ApoL1 is linked to Focal segmental glomerulosclerosis 4, a renal disease characterized by glomeruli damage and progressive renal failure. Understanding ApoL1's function and its genetic variants offers a pathway to novel treatments for this condition.